WO1999003881A3 - Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique - Google Patents

Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique Download PDF

Info

Publication number
WO1999003881A3
WO1999003881A3 PCT/FR1998/001573 FR9801573W WO9903881A3 WO 1999003881 A3 WO1999003881 A3 WO 1999003881A3 FR 9801573 W FR9801573 W FR 9801573W WO 9903881 A3 WO9903881 A3 WO 9903881A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragment
shiga toxin
peptides
therapeutic interest
chimeric polypeptide
Prior art date
Application number
PCT/FR1998/001573
Other languages
English (en)
Other versions
WO1999003881A2 (fr
Inventor
Bruno Goud
Ludger Johannes
Original Assignee
Inst Curie
Centre Nat Rech Scient
Bruno Goud
Ludger Johannes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU88124/98A priority Critical patent/AU750367B2/en
Priority to DK98939705T priority patent/DK1017715T3/da
Priority to CA2296711A priority patent/CA2296711C/fr
Priority to JP2000503103A priority patent/JP4541538B2/ja
Priority to EP98939705A priority patent/EP1017715B1/fr
Priority to DE69839566T priority patent/DE69839566D1/de
Application filed by Inst Curie, Centre Nat Rech Scient, Bruno Goud, Ludger Johannes filed Critical Inst Curie
Publication of WO1999003881A2 publication Critical patent/WO1999003881A2/fr
Priority to US09/484,471 priority patent/US6613882B1/en
Publication of WO1999003881A3 publication Critical patent/WO1999003881A3/fr
Priority to HK01100304A priority patent/HK1030613A1/xx
Priority to US10/443,614 priority patent/US7488809B2/en
Priority to US12/347,677 priority patent/US8524652B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Abstract

L'invention se rapporte à une séquence polypeptidique comprenant le fragment B de la toxine de Shiga ou un équivalent fonctionnel de celui-ci liée à l'extrémité carboxy-terminale à un ou plusieurs polypeptides répondant à la formule B - X dans laquelle B représente le fragment B de la toxine de Shiga et X représente un ou plusieurs polypeptides d'intérêt thérapeutique, et son utilisation comme principe actif d'une composition thérapeutique.
PCT/FR1998/001573 1997-07-18 1998-07-17 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique WO1999003881A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK98939705T DK1017715T3 (da) 1997-07-18 1998-07-17 Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
CA2296711A CA2296711C (fr) 1997-07-18 1998-07-17 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
JP2000503103A JP4541538B2 (ja) 1997-07-18 1998-07-17 志賀毒素のｂフラグメント及び治療向けペプチドを含むキメラポリペプチド
EP98939705A EP1017715B1 (fr) 1997-07-18 1998-07-17 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
DE69839566T DE69839566D1 (de) 1997-07-18 1998-07-17 Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
AU88124/98A AU750367B2 (en) 1997-07-18 1998-07-17 Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
US09/484,471 US6613882B1 (en) 1997-07-18 2000-01-18 Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest
HK01100304A HK1030613A1 (en) 1997-07-18 2001-01-11 Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
US10/443,614 US7488809B2 (en) 1997-07-18 2003-05-21 Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest
US12/347,677 US8524652B2 (en) 1997-07-18 2008-12-31 Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR97/09185 1997-07-18
FR9709185A FR2766193B1 (fr) 1997-07-18 1997-07-18 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/484,471 Continuation US6613882B1 (en) 1997-07-18 2000-01-18 Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest

Publications (2)

Publication Number Publication Date
WO1999003881A2 WO1999003881A2 (fr) 1999-01-28
WO1999003881A3 true WO1999003881A3 (fr) 2000-06-29

Family

ID=9509394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1998/001573 WO1999003881A2 (fr) 1997-07-18 1998-07-17 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique

Country Status (13)

Country Link
US (4) US6613882B1 (fr)
EP (1) EP1017715B1 (fr)
JP (2) JP4541538B2 (fr)
CN (1) CN1272882A (fr)
AT (1) ATE397062T1 (fr)
AU (1) AU750367B2 (fr)
CA (1) CA2296711C (fr)
DE (1) DE69839566D1 (fr)
DK (1) DK1017715T3 (fr)
ES (1) ES2307323T3 (fr)
FR (1) FR2766193B1 (fr)
HK (1) HK1030613A1 (fr)
WO (1) WO1999003881A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4820000B2 (ja) * 1998-05-15 2011-11-24 アラン エム グリーン 免疫処置のためのベロ毒素ｂサブユニット
EP1057895A1 (fr) * 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Protéine de fusion comprenant le fragment B de la toxine de Shiga, préparation (vaccinale) la comprenant, et procédé pour leur préparation
US20040071739A1 (en) * 1999-11-15 2004-04-15 Select Therapeutics, Inc. Methods of preparing an anti-tumor vaccine
EP1229045A1 (fr) 2001-02-01 2002-08-07 Institut Curie Support universel pour le ciblage de molécules sur des cellules exprimant le récepteur Gb3
ATE292144T1 (de) 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
PL2308514T3 (pl) * 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US20090214438A1 (en) * 2007-12-18 2009-08-27 Institut Curie Methods and compositions for the preparation and use of toxin conjugates
EP2072060A1 (fr) 2007-12-18 2009-06-24 Institut Curie Procédés et compositions pour la préparation et l'utilisation de conjugués de toxines
EP2591602A1 (fr) 2010-07-06 2013-05-15 Koninklijke Philips Electronics N.V. Génération d'images à grande gamme dynamique à partir d'images à faible gamme dynamique
EP2548571A1 (fr) 2011-07-22 2013-01-23 Institut Curie Compositions dotées de supports de ciblage d'au moins un antigène sur des cellules dendritiques
EP2740491A1 (fr) 2012-12-05 2014-06-11 Institut Curie Conjugués de la sous-unité b de la toxine de shiga destinés à être utilisés comme agents de contraste pour l'imagerie et la thérapie
EP2740493A1 (fr) 2012-12-05 2014-06-11 Institut Curie Conjugués de la sous-unité B de la toxine de Shiga dans des thérapies anticancéreuses
AU2015209065C1 (en) 2014-01-27 2019-09-26 Molecular Templates, Inc. De-immunized Shiga toxin A Subunit effector polypeptides for applications in mammals
EP3058956A1 (fr) 2015-02-23 2016-08-24 Institut Curie Vaccination/radiothérapie combinée pour le traitement du cancer
CN104744594B (zh) * 2015-04-21 2018-09-18 中国人民解放军第三军医大学 乙肝病毒多表位与志贺毒素的融合蛋白及其制备方法和应用
PL3303373T3 (pl) * 2015-05-30 2020-09-21 Molecular Templates, Inc. Deimmunizowane rusztowania podjednostki a toksyny shiga oraz zawierające je cząsteczki nakierowane na komórki
KR20180030085A (ko) * 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
CN114773439A (zh) 2016-12-07 2022-07-22 分子模板公司 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
CN116236584B (zh) * 2023-02-20 2024-03-22 四川大学 一种用于高效递送siRNA的多糖-多肽偶联物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0439954A2 (fr) * 1989-12-22 1991-08-07 Seragen, Inc. Molécules hybrides ayant une région de translocation et une région d'attachement aux cellules
WO1993016186A1 (fr) * 1992-02-17 1993-08-19 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Adn hybride qui code une unite secondaire d'une toxine bacterienne avec une hemolysine
WO1993017115A2 (fr) * 1992-02-18 1993-09-02 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Vaccin anti-dysenterique stimulant une reponse immunitaire contre la toxine shiga, et plasmides et souches associes
WO1997013410A1 (fr) * 1995-10-13 1997-04-17 Boston Medical Center Corporation Molecules hybrides contenant des ligands amides fixant les polypeptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2547731A1 (fr) 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US5198344A (en) 1986-07-15 1993-03-30 Massachusetts Institute Of Technology DNA sequence that encodes the multidrug resistance gene
US5338839A (en) 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
KR910014970A (ko) 1990-01-08 1991-08-31 미다 가쓰시게 가스 차단기
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
CA2077277A1 (fr) 1991-09-09 1993-03-10 John J. Donnelly Vaccins a base de conjugues toxine bacterienne-antigene procurant une immunite a mediation cellulaire
US5350890A (en) 1992-10-01 1994-09-27 Gould Instrument Systems, Inc. Contact switch device
DE69434951D1 (de) 1993-02-22 2007-05-24 Gen Hospital Corp Heterologe antigene in stämmen zur impfung mit lebendzellen
US7229755B1 (en) 1993-11-17 2007-06-12 Dana Farber Cancer Institute, Inc. Method for detection of alterations in the DNA mismatch repair pathway
US5763165A (en) 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
WO1996016178A1 (fr) 1994-11-17 1996-05-30 Maxim Pharmaceuticals, Inc. Immunogenes pour stimuler l'immunite des muqueuses
EP0739984A1 (fr) 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Polypeptides bivalents contenants aux moins deux domaines
AU4184597A (en) 1996-09-10 1998-04-02 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6482586B1 (en) 1996-11-22 2002-11-19 Hospital For Sick Children Research And Development Limited Partnership Hybrid compositions for intracellular targeting
JP4820000B2 (ja) 1998-05-15 2011-11-24 アラン エム グリーン 免疫処置のためのベロ毒素ｂサブユニット

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0439954A2 (fr) * 1989-12-22 1991-08-07 Seragen, Inc. Molécules hybrides ayant une région de translocation et une région d'attachement aux cellules
WO1993016186A1 (fr) * 1992-02-17 1993-08-19 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Adn hybride qui code une unite secondaire d'une toxine bacterienne avec une hemolysine
WO1993017115A2 (fr) * 1992-02-18 1993-09-02 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Vaccin anti-dysenterique stimulant une reponse immunitaire contre la toxine shiga, et plasmides et souches associes
WO1997013410A1 (fr) * 1995-10-13 1997-04-17 Boston Medical Center Corporation Molecules hybrides contenant des ligands amides fixant les polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A RAPAK ET AL.: "Retrograde transport of mutant ricin to the endoplasmic reticulum with subsequent translocation to the cytosol", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 94, April 1997 (1997-04-01), WASHINGTON US, pages 3783 - 3788, XP002061694 *
L JOHANNES & B GOUD: "Shiga toxin as a tool to study retrograde transport", ANNUAL MEETING OF THE 6TH INTERNATIONAL CONGRESS ON CELL BIOLOGY AND THE 36TH AMERICAN SOCIETY FOR CELL BIOLOGY, SAN FRANCISCO, CALIFORNIA, USA, DECEMBER 7-11, 1996. MOLECULAR BIOLOGY OF THE CELL, vol. 7, no. suppl., 1996, pages 75a, XP002061695 *
L JOHANNES ET AL.: "Retrograde transport of KDEL-bearing B-fragment of Shiga toxin", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 272, no. 31, 1 August 1997 (1997-08-01), MD US, pages 19554 - 19561, XP002061696 *

Also Published As

Publication number Publication date
AU8812498A (en) 1999-02-10
DK1017715T3 (da) 2008-10-06
US6613882B1 (en) 2003-09-02
CA2296711A1 (fr) 1999-01-28
FR2766193B1 (fr) 2001-09-14
JP4541538B2 (ja) 2010-09-08
ES2307323T3 (es) 2008-11-16
US20170015719A1 (en) 2017-01-19
EP1017715B1 (fr) 2008-05-28
AU750367B2 (en) 2002-07-18
ATE397062T1 (de) 2008-06-15
EP1017715A2 (fr) 2000-07-12
US7488809B2 (en) 2009-02-10
US20040047883A1 (en) 2004-03-11
DE69839566D1 (de) 2008-07-10
WO1999003881A2 (fr) 1999-01-28
US8524652B2 (en) 2013-09-03
JP2010180216A (ja) 2010-08-19
HK1030613A1 (en) 2001-05-11
FR2766193A1 (fr) 1999-01-22
CN1272882A (zh) 2000-11-08
US20100322913A1 (en) 2010-12-23
CA2296711C (fr) 2012-07-03
JP2001510030A (ja) 2001-07-31

Similar Documents

Publication Publication Date Title
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
WO2001075067A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057188A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002031111A3 (fr) Acides nucleiques et polypeptides
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002010195A3 (fr) Peptides biologiques modifies presentant une activite renforcee
HU9502920D0 (en) New bacillus thuringiensis strains and their insecticidal proteins
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
WO1999000407A3 (fr) Toxine de bacillus thuringiensis amelioree
WO2002044340A3 (fr) Nouveaux acides nucleiques et polypeptides
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
WO2001070808A3 (fr) Proteines associees a l'angiogenese et acides nucleiques codant ces proteines
WO2001075093A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001087917A8 (fr) Nouveaux acides nucleiques et polypeptides
AU9362801A (en) A novel polypeptide, a human protein 10 containing a group and the polynucleotide encoding the polypeptide
GB9604518D0 (en) Novel compounds
EP1591448A3 (fr) Nouveaux acides nucleiques et polypeptides
AU2001233567A1 (en) A novel polypeptide, human protein 9 of short-chain scorpion toxin and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98808796.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2296711

Country of ref document: CA

Ref document number: 2296711

Country of ref document: CA

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09484471

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998939705

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 88124/98

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1998939705

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 88124/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998939705

Country of ref document: EP